Intervention
ramipril
ClinicalTrials.gov intervention label
Clinical trials
11 shownEmpagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN StudyNCT02632747 · 2016-05-10
COMPLETEDBenazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid TumorsNCT01234922 · 2011-02-01
TERMINATEDPerindopril vs Ramipril for Persistence in MAU Reduction StudyNCT02729441 · 2010-04-01
COMPLETEDEffects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart FailureNCT00923156 · 2009-05-01
COMPLETEDEffect of Renin Angiotensin System Blockade on the Fas Antigen (CD95) and Asymmetric Dimethylarginine (ADMA) Levels in Type-2 Diabetic Patients With ProteinuriaNCT00893425 · 2008-01-01
COMPLETEDLeft Atrial Remodelling in Hypertension: Effects of Ramipril or IrbesartanNCT00517322 · 2007-08-01
UNKNOWNA Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and AdolescentsNCT00389519 · 2006-10-01
TERMINATEDHigher Dose of Ramipril Versus Addition of Telmisartan-Ramipril in Hypertension and DiabetesNCT00208221 · 2006-08-01
TERMINATEDThe Effect of Renin Angiotensin System Blockage (RAS) Blockade On PTX3 Levels In Diabetic Patients With ProteinuriaNCT00674596 · 2006-01-01
COMPLETEDNephropathy In Type 2 Diabetes and Cardio-renal EventsNCT00535925 · 2005-10-01
COMPLETEDTreatment of Pediatric Hypertension With Altace TrialNCT00044265 · 2002-07-01
COMPLETEDCommon conditions
Hypertension4Diabetes2Diabetic Nephropathy2Proteinuria2Renin Angiotensin System2Albuminuria1Antihypertensive Drugs1Chronic Kidney Disease1Diabetes Mellitus, Type 11Diabetes Mellitus, Type 21Diastolic Function1Heart Failure1Hypertensive Heart Disease1Left Atrial Volume1Microalbuminuria1Obesity1Type 2 Diabetes1Unspecified Adult Solid Tumor, Protocol Specific1
Leading sponsors
Trial status mix
COMPLETED7
TERMINATED3
UNKNOWN1
Phase mix
PHASE45
PHASE23
PHASE33
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.